References
- Abdelbaset, M., Safar, M. M., Mahmoud, S. S., Negm, S. A., Agha, A. M. (2014). Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats. Can. J. Physiol. Pharmacol., 92 (6), 481–489.
- Abourjaily, H. M., Alsheikh-Ali, A. A., Karas, R. H. (2003). Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin. Amer. J. Cardiol., 91 (8), 999–1002.
- Baker, S. K. (2005). Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve, 31 (5), 572–580.
- Ballard, K. D., Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., Thompson, P. D. (2013). Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis, 230 (1), 121–124.
- Bays, H. (2006). Statin safety: An overview and assessment of the data-2005. Amer. J. Cardiol., 97 (8A), 6C–26C.
- Bitzur, R., Cohen, H., Kamari, Y., Harats, D. (2013). Intolerance to statins: Mechanisms and management. Diabetes Care, 36 (2), S325–S330.
- Bizzarri, R., Cerbai, B., Signori, F. (2003). New perspectives for (S)-dolichol and (S)-nor dolichol synthesis and biological functions. Biogerontology, 4 (6), 353–363.
- Buhaescu, I., Izzedine, H. (2007). Mevalonate pathway: a review of clinical and therapeutical implications. Clin. Biochem., 40 (9–10), 575–584.
- Camerino, G. M., Pellegrino, M. A., Brocca, L. (2011). Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle. Biochem. Pharm., 81 (8), 1054–1064.
- Cantagrel, V., Lefeber, D. J. (2011). From glycosylation disorders to dolichol biosynthesis defects: A new class of metabolic diseases. J. Inherit. Metab. Dis., 34 (4), 859–867.
- Chojnacki, T., Dallner, G. (1983). The uptake of dietary polyprenols and their modification to active dolichols by the rat liver. J. Biol. Chem.,258 (2), 916–922.
- Chojnacki, T., Dallner, G. (1988). The biological role of dolichol. Biochem. J.,251 (1), 1–9.
- Dwajani, S., Kumar, V. S., Keerthi, D. (2012). Atorvastatin and simvastatin as analgesic agents in experimental models. J. Basic Clin. Pharm., 3 (4), 332–335.
- Fedotova, J. O., Sultanov, V. S., Kuznetsova, N. N. (2010). Effect of new polyprenol drug ropren on anxiety-depressive-like behavior in rats with experimental Alzheimer disease. Eksp. Klin. Farmakol.,73 (9), 2–5.
- Fedotova, J., Soultanov, V., Nikitina, T. (2012). Ropren® is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25-35)-induced amnesia. Phytomedicine, 19 (5), 451–456.
- Garcia, G. G., Miranda, H. F., Noriega, V. (2011). Antinociception induced by atorvastatin in different pain models. Pharmacol. Biochem. Behav., 100 (1), 125–129.
- Hartley, M. D., Imperiali, B. (2012). At the membrane frontier: a prospectus on the remarkable evolutionary conservation of polyprenols and polyprenyl-phosphates. Arch. Biochem. Biophys., 517 (2), 83–97.
- Jaiswal, S. R., Sontakke, S. D. (2012). Experimental evaluation of analgesic and anti-inflammatory activity of simvastatin and atorvastatin. Indian J. Pharmacol., 44 (4), 475–479.
- Jakobsson, A., Swiezewska, E., Chojnacki, T. (1989). Uptake and modification of dietary polyprenols and dolichols in rat liver. FEBS Lett, 255 (1), 32–36.
- Laaksonen, R. (2013). STOMPing forward: Statins, muscle complaints and CK. Atherosclerosis, 230 (2), 256–257.
- Madsen, C. S., Janovitz, E., Zhang, R. (2008). The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins. J. Pharmacol. Exp. Ther., 324 (2), 576–586.
- Mazroa, S. A., Asker, S. A. (2010). Myotoxic effects of atorvastatin drug (Lipitor) on the skeletal muscles of adult Mmale albino rats and the effect of L-carnitine co-administration light microscopical, immunohistochemical and biochemical Study. Egypt. J. Histol.,33 (3), 520–531.
- Manoukian, A. A., Bhagavan, N. V., Hayashi, T. (1990). Rhabdomyolysis secondary to lovastatin therapy. Clin. Chem., 36 (12), 2145–2147.
- Milenkovic, D., Jude, B., Morand, C. (2013). miRNA as molecular target of polyphenols underlying their biological effects. Free Radic. Biol. Med., 64, 40–51.
- Pronin, A. V., Danilov, L. L., Narovlyansky, A. N. (2014). Plant polyisoprenoids and control of cholesterol level. Arch. Immunol. Ther. Exp. (Warsz), 62 (1), 31–39.
- Rosenson, R. S., Baker, S. K., Jacobson, T. A. (2014). An assessment by the Statin Muscle Safety Task Force: 2014 update. J. Clin. Lipidol.,8 (3), S58–S71.
- Sathasivam, S., Lecky, B. (2008). Statin induced myopathy. British Medical Journal (BMJ),337, a2286.
- Sierra, S., Ramos, M. C., Molina, P. (2011). Statins as neuroprotectants:A comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J. Alzheimers Dis., 23 (2), 307–318.
- Soner, B. C., Inan, S. Y., Güven, U. (2013). Combined treatment with resveratrol prevents the atorvastatin-induced myopathy in rat skeletal muscle. Afr. J. Pharm. Pharmacol.,7 (18), 1114–1118.
- Surmacz, L., Swiezewska, E. (2011). Polyisoprenoids — secondary metabolites or physiologically important superlipids? Biochem. Biophys. Res. Commun., 407 (4), 627–632.
- Tuccori, M., Montagnani, S., Mantarro, S. (2014). Neuropsychiatric adverse events associated with statins: Epidemiology, pathophysiology, prevention and management. Central Nervous System Drugs, 28 (3), 249–272.
- van der Most, P. J., Dolga, A. M., Nijholt, I. M. (2009). Statins: Mechanisms of neuroprotection. Prog. Neurobiol., 88 (1), 64–75.
- Wagstaff, L. R, Mitton, M. W., Arvik, B. M. (2003). Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacother, 23 (7), 871–880.
- Wang, C. Z., Wang, W. L., Ye, J. Z. (2008). Studies on separation of polyprenols from leaves of Ginkgo biloba L. by molecular short distillation. Chemistry and Industry of Forest Products, 28 (3), 23–27.
- Wang, C., He, L., Yan, M. (2014). Effects of polyprenols from needles of Pinus massoniana on ameliorating cognitive impairment in a d-galactose-induced mouse model. Age (Dordr), 36 (4), 9676.
- Werner, M., Sacher, J., Hohenegger, M. (2004). Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Brit. J. Pharmacol.,143 (6), 715–724.
- Wilkinson, M. J., Laffin, L. J., Davidson, M. H. (2014). Overcoming toxicity and side-effects of lipid-lowering therapies. Best Pract. Res. Clin. Endocrinol. Metab.,28 (3), 439–452.